{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T18:03:11Z","timestamp":1787162591727,"version":"build-2736575974"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T00:00:00Z","timestamp":1745193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS120062-01A1"],"award-info":[{"award-number":["NS120062-01A1"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006514","name":"East Tennessee State University","doi-asserted-by":"publisher","award":["Research Enhancement Award 2023"],"award-info":[{"award-number":["Research Enhancement Award 2023"]}],"id":[{"id":"10.13039\/100006514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006514","name":"East Tennessee State University","doi-asserted-by":"publisher","award":["825-30"],"award-info":[{"award-number":["825-30"]}],"id":[{"id":"10.13039\/100006514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006514","name":"East Tennessee State University","doi-asserted-by":"publisher","award":["E85096"],"award-info":[{"award-number":["E85096"]}],"id":[{"id":"10.13039\/100006514","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006514","name":"East Tennessee State University","doi-asserted-by":"publisher","award":["E85078"],"award-info":[{"award-number":["E85078"]}],"id":[{"id":"10.13039\/100006514","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06475-6","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T11:10:33Z","timestamp":1745233833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Efficacy of MET-targeting CAR T cells against glioblastoma patient-derived xenograft models"],"prefix":"10.1186","volume":"23","author":[{"given":"Anna","family":"Qin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Musket","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Hilton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Preiszner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giedre","family":"Krenciute","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Berens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingyao","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip R.","family":"Musich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4206-1736","authenticated-orcid":false,"given":"Qian","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,21]]},"reference":[{"issue":"12","key":"6475_CR1","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1093\/neuonc\/nou147","volume":"16","author":"Q Xie","year":"2014","unstructured":"Xie Q, Mittal S, Berens ME. Targeting adaptive glioblastoma: an overview of proliferation and invasion. Neuro Oncol. 2014;16(12):1575\u201384.","journal-title":"Neuro Oncol"},{"issue":"18","key":"6475_CR2","first-page":"5821","volume":"63","author":"SK Singh","year":"2003","unstructured":"Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003;63(18):5821\u20138.","journal-title":"Cancer Res"},{"key":"6475_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1476-4598-5-67","volume":"5","author":"G Liu","year":"2006","unstructured":"Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer. 2006;5:67.","journal-title":"Mol Cancer"},{"issue":"7120","key":"6475_CR4","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1038\/nature05236","volume":"444","author":"S Bao","year":"2006","unstructured":"Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006;444(7120):756\u201360.","journal-title":"Nature"},{"issue":"5","key":"6475_CR5","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ccr.2006.03.030","volume":"9","author":"J Lee","year":"2006","unstructured":"Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM, Pastorino S, Purow BW, Christopher N, Zhang W, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006;9(5):391\u2013403.","journal-title":"Cancer Cell"},{"issue":"7216","key":"6475_CR6","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/nature07385","volume":"455","author":"Cancer Genome Atlas Research N","year":"2008","unstructured":"Cancer Genome Atlas Research N. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061\u20138.","journal-title":"Nature"},{"issue":"1","key":"6475_CR7","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00401-015-1420-5","volume":"130","author":"AC Navis","year":"2015","unstructured":"Navis AC, van Lith SA, van Duijnhoven SM, de Pooter M, Yetkin-Arik B, Wesseling P, Hendriks WJ, Venselaar H, Timmer M, van Cleef P, et al. Identification of a novel MET mutation in high-grade glioma resulting in an auto-active intracellular protein. Acta Neuropathol. 2015;130(1):131\u201344.","journal-title":"Acta Neuropathol"},{"issue":"11","key":"6475_CR8","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1101\/gr.165126.113","volume":"24","author":"ZS Bao","year":"2014","unstructured":"Bao ZS, Chen HM, Yang MY, Zhang CB, Yu K, Ye WL, Hu BQ, Yan W, Zhang W, Akers J, et al. RNA-seq of 272 gliomas revealed a novel, recurrent PTPRZ1-MET fusion transcript in secondary glioblastomas. Genome Res. 2014;24(11):1765\u201373.","journal-title":"Genome Res"},{"issue":"2","key":"6475_CR9","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1073\/pnas.1119059109","volume":"109","author":"Q Xie","year":"2012","unstructured":"Xie Q, Bradley R, Kang L, Koeman J, Ascierto ML, Worschech A, De Giorgi V, Wang E, Kefene L, Su Y, et al. Hepatocyte growth factor (HGF) autocrine activation predicts sensitivity to MET inhibition in glioblastoma. Proc Natl Acad Sci U S A. 2012;109(2):570\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"6475_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s12094-013-1059-4","volume":"16","author":"OF Olmez","year":"2014","unstructured":"Olmez OF, Cubukcu E, Evrensel T, Kurt M, Avci N, Tolunay S, Bekar A, Deligonul A, Hartavi M, Alkis N, et al. The immunohistochemical expression of c-Met is an independent predictor of survival in patients with glioblastoma multiforme. Clin Transl Oncol. 2014;16(2):173\u20137.","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"6475_CR11","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1007\/s11060-015-1723-3","volume":"122","author":"SA Petterson","year":"2015","unstructured":"Petterson SA, Dahlrot RH, Hermansen SK, Munthe SKA, Gundesen MT, Wohlleben H, Rasmussen T, Beier CP, Hansen S, Kristensen BW. High levels of c-Met is associated with poor prognosis in glioblastoma. J Neurooncol. 2015;122(3):517\u201327.","journal-title":"J Neurooncol"},{"issue":"1","key":"6475_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jocn.2010.05.010","volume":"18","author":"W Liu","year":"2011","unstructured":"Liu W, Fu Y, Xu S, Ding F, Zhao G, Zhang K, Du C, Pang B, Pang Q. c-Met expression is associated with time to recurrence in patients with glioblastoma multiforme. J Clin Neurosci. 2011;18(1):119\u201321.","journal-title":"J Clin Neurosci"},{"issue":"1","key":"6475_CR13","doi-asserted-by":"publisher","first-page":"6067","DOI":"10.1038\/s41598-021-85385-1","volume":"11","author":"B Carvalho","year":"2021","unstructured":"Carvalho B, Lopes JM, Silva R, Peixoto J, Leitao D, Soares P, Fernandes AC, Linhares P, Vaz R, Lima J. The role of c-Met and VEGFR2 in glioblastoma resistance to bevacizumab. Sci Rep. 2021;11(1):6067.","journal-title":"Sci Rep"},{"issue":"1","key":"6475_CR14","first-page":"vdaa067","volume":"2","author":"Y Qin","year":"2020","unstructured":"Qin Y, Musket A, Kou J, Preiszner J, Tschida BR, Qin A, Land CA, Staal B, Kang L, Tanner K, et al. Overexpression of HGF\/MET axis along with p53 inhibition induces de novo glioma formation in mice. Neurooncol Adv. 2020;2(1):vdaa067.","journal-title":"Neurooncol Adv"},{"issue":"8","key":"6475_CR15","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/onc.2014.29","volume":"34","author":"CV Camacho","year":"2015","unstructured":"Camacho CV, Todorova PK, Hardebeck MC, Tomimatsu N, Gil del Alcazar CR, Ilcheva M, Mukherjee B, McEllin B, Vemireddy V, Hatanpaa K, et al. DNA double-strand breaks cooperate with loss of Ink4 and Arf tumor suppressors to generate glioblastomas with frequent Met amplification. Oncogene. 2015;34(8):1064\u201372.","journal-title":"Oncogene"},{"issue":"24","key":"6475_CR16","doi-asserted-by":"publisher","first-page":"9951","DOI":"10.1073\/pnas.1016912108","volume":"108","author":"Y Li","year":"2011","unstructured":"Li Y, Li A, Glas M, Lal B, Ying M, Sang Y, Xia S, Trageser D, Guerrero-Cazares H, Eberhart CG, et al. c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A. 2011;108(24):9951\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"15","key":"6475_CR17","doi-asserted-by":"publisher","first-page":"3828","DOI":"10.1158\/0008-5472.CAN-11-3760","volume":"72","author":"KM Joo","year":"2012","unstructured":"Joo KM, Jin J, Kim E, Ho Kim K, Kim Y, Gu Kang B, Kang YJ, Lathia JD, Cheong KH, Song PH, et al. MET signaling regulates glioblastoma stem cells. Cancer Res. 2012;72(15):3828\u201338.","journal-title":"Cancer Res"},{"issue":"8","key":"6475_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/nrd4406","volume":"13","author":"K Garber","year":"2014","unstructured":"Garber K. MET inhibitors start on road to recovery. Nat Rev Drug Discov. 2014;13(8):563\u20135.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"6475_CR19","first-page":"vdab133","volume":"3","author":"A Qin","year":"2021","unstructured":"Qin A, Musket A, Musich PR, Schweitzer JB, Xie Q. Receptor tyrosine kinases as druggable targets in glioblastoma: do signaling pathways matter? Neurooncol Adv. 2021;3(1):vdab133.","journal-title":"Neurooncol Adv"},{"issue":"1","key":"6475_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1186\/s12967-020-02598-0","volume":"18","author":"CA Land","year":"2020","unstructured":"Land CA, Musich PR, Haydar D, Krenciute G, Xie Q. Chimeric antigen receptor T-cell therapy in glioblastoma: charging the T cells to fight. J Transl Med. 2020;18(1):428.","journal-title":"J Transl Med"},{"issue":"8","key":"6475_CR21","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1158\/1078-0432.CCR-11-1669","volume":"18","author":"CE Brown","year":"2012","unstructured":"Brown CE, Starr R, Aguilar B, Shami AF, Martinez C, D\u2019Apuzzo M, Barish ME, Forman SJ, Jensen MC. Stem-like tumor-initiating cells isolated from IL13Ralpha2 expressing gliomas are targeted and killed by IL13-zetakine-redirected T Cells. Clin Cancer Res. 2012;18(8):2199\u2013209.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"6475_CR22","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1089\/hum.2012.041","volume":"23","author":"RA Morgan","year":"2012","unstructured":"Morgan RA, Johnson LA, Davis JL, Zheng Z, Woolard KD, Reap EA, Feldman SA, Chinnasamy N, Kuan CT, Song H, et al. Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther. 2012;23(10):1043\u201353.","journal-title":"Hum Gene Ther"},{"issue":"2","key":"6475_CR23","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1158\/1078-0432.CCR-09-1322","volume":"16","author":"N Ahmed","year":"2010","unstructured":"Ahmed N, Salsman VS, Kew Y, Shaffer D, Powell S, Zhang YJ, Grossman RG, Heslop HE, Gottschalk S. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2):474\u201385.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"6475_CR24","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.cell.2018.09.038","volume":"175","author":"H Hu","year":"2018","unstructured":"Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, et al. Mutational landscape of secondary glioblastoma guides MET-targeted trial in brain tumor. Cell. 2018;175(6):1665-1678 e1618.","journal-title":"Cell"},{"issue":"11","key":"6475_CR25","first-page":"14932","volume":"8","author":"Y Kwak","year":"2015","unstructured":"Kwak Y, Kim SI, Park CK, Paek SH, Lee ST, Park SH. C-MET overexpression and amplification in gliomas. Int J Clin Exp Pathol. 2015;8(11):14932\u20138.","journal-title":"Int J Clin Exp Pathol"},{"issue":"32","key":"6475_CR26","doi-asserted-by":"publisher","first-page":"E2987","DOI":"10.1073\/pnas.1302725110","volume":"110","author":"M Merchant","year":"2013","unstructured":"Merchant M, Ma X, Maun HR, Zheng Z, Peng J, Romero M, Huang A, Yang NY, Nishimura M, Greve J, et al. Monovalent antibody design and mechanism of action of onartuzumab, a MET antagonist with anti-tumor activity as a therapeutic agent. Proc Natl Acad Sci U S A. 2013;110(32):E2987-2996.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"6475_CR27","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1200\/JCO.2015.64.7685","volume":"35","author":"T Cloughesy","year":"2017","unstructured":"Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR. Randomized, double-blind, placebo-controlled, multicenter phase II study of onartuzumab plus bevacizumab versus placebo plus bevacizumab in patients with recurrent glioblastoma: efficacy, safety, and hepatocyte growth factor and O (6)-methylguanine-DNA methyltransferase biomarker analyses. J Clin Oncol. 2017;35(3):343\u201351.","journal-title":"J Clin Oncol"},{"issue":"1","key":"6475_CR28","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12967-023-04521-9","volume":"21","author":"A Qin","year":"2023","unstructured":"Qin A, Qin Y, Lee J, Musket A, Ying M, Krenciute G, Marincola FM, Yao ZQ, Musich PR, Xie Q. Tyrosine kinase signaling-independent MET-targeting with CAR-T cells. J Transl Med. 2023;21(1):682.","journal-title":"J Transl Med"},{"issue":"5","key":"6475_CR29","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1158\/2767-9764.CRC-22-0486","volume":"3","author":"PD Shah","year":"2023","unstructured":"Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, et al. Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma. Cancer Res Commun. 2023;3(5):821\u20139.","journal-title":"Cancer Res Commun"},{"key":"6475_CR30","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12967-015-0667-x","volume":"13","author":"J Johnson","year":"2015","unstructured":"Johnson J, Ascierto ML, Mittal S, Newsome D, Kang L, Briggs M, Tanner K, Marincola FM, Berens ME, Vande Woude GF, et al. Genomic profiling of a Hepatocyte growth factor-dependent signature for MET-targeted therapy in glioblastoma. J Transl Med. 2015;13:306.","journal-title":"J Transl Med"},{"issue":"8","key":"6475_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010483","volume":"18","author":"RA Stein","year":"2022","unstructured":"Stein RA, McHaourab HS. SPEACH_AF: sampling protein ensembles and conformational heterogeneity with Alphafold2. PLoS Comput Biol. 2022;18(8): e1010483.","journal-title":"PLoS Comput Biol"},{"issue":"6","key":"6475_CR32","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41592-022-01488-1","volume":"19","author":"M Mirdita","year":"2022","unstructured":"Mirdita M, Schutze K, Moriwaki Y, Heo L, Ovchinnikov S, Steinegger M. ColabFold: making protein folding accessible to all. Nat Methods. 2022;19(6):679\u201382.","journal-title":"Nat Methods"},{"issue":"3","key":"6475_CR33","doi-asserted-by":"publisher","first-page":"284","DOI":"10.4161\/cib.3.3.11656","volume":"3","author":"S Bouyain","year":"2010","unstructured":"Bouyain S, Watkins DJ. Identification of tyrosine phosphatase ligands for contactin cell adhesion molecules. Commun Integr Biol. 2010;3(3):284\u20136.","journal-title":"Commun Integr Biol"},{"issue":"6","key":"6475_CR34","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1073\/pnas.0911235107","volume":"107","author":"S Bouyain","year":"2010","unstructured":"Bouyain S, Watkins DJ. The protein tyrosine phosphatases PTPRZ and PTPRG bind to distinct members of the contactin family of neural recognition molecules. Proc Natl Acad Sci U S A. 2010;107(6):2443\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"6475_CR35","doi-asserted-by":"publisher","first-page":"4074","DOI":"10.1038\/s41467-021-24367-3","volume":"12","author":"E Uchikawa","year":"2021","unstructured":"Uchikawa E, Chen Z, Xiao GY, Zhang X, Bai XC. Structural basis of the activation of c-MET receptor. Nat Commun. 2021;12(1):4074.","journal-title":"Nat Commun"},{"issue":"5","key":"6475_CR36","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1158\/1078-0432.CCR-19-0909","volume":"26","author":"RA Vaubel","year":"2020","unstructured":"Vaubel RA, Tian S, Remonde D, Schroeder MA, Mladek AC, Kitange GJ, Caron A, Kollmeyer TM, Grove R, Peng S, et al. Genomic and phenotypic characterization of a broad panel of patient-derived xenografts reflects the diversity of glioblastoma. Clin Cancer Res. 2020;26(5):1094\u2013104.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6475_CR37","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12967-018-1628-y","volume":"16","author":"J Kou","year":"2018","unstructured":"Kou J, Musich PR, Staal B, Kang L, Qin Y, Yao ZQ, Zhang B, Wu W, Tam A, Huang A, et al. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody. J Transl Med. 2018;16(1):253.","journal-title":"J Transl Med"},{"issue":"17","key":"6475_CR38","doi-asserted-by":"publisher","first-page":"5697","DOI":"10.1158\/0008-5472.CAN-11-0103","volume":"71","author":"M Chmielewski","year":"2011","unstructured":"Chmielewski M, Kopecky C, Hombach AA, Abken H. IL-12 release by engineered T cells expressing chimeric antigen receptors can effectively Muster an antigen-independent macrophage response on tumor cells that have shut down tumor antigen expression. Cancer Res. 2011;71(17):5697\u2013706.","journal-title":"Cancer Res"},{"issue":"7","key":"6475_CR39","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1158\/2326-6066.CIR-16-0376","volume":"5","author":"G Krenciute","year":"2017","unstructured":"Krenciute G, Prinzing BL, Yi Z, Wu MF, Liu H, Dotti G, Balyasnikova IV, Gottschalk S. Transgenic expression of IL15 improves antiglioma activity of IL13Ralpha2-CAR T cells but results in antigen loss variants. Cancer Immunol Res. 2017;5(7):571\u201381.","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"6475_CR40","doi-asserted-by":"publisher","DOI":"10.1172\/JCI166028","volume":"133","author":"JE Jaspers","year":"2023","unstructured":"Jaspers JE, Khan JF, Godfrey WD, Lopez AV, Ciampricotti M, Rudin CM, Brentjens RJ. IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models. J Clin Invest. 2023;133(9): e166028.","journal-title":"J Clin Invest"},{"issue":"1","key":"6475_CR41","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-024-01792-6","volume":"9","author":"W Zhu","year":"2024","unstructured":"Zhu W, Zhang Z, Chen J, Chen X, Huang L, Zhang X, Huang X, Ma N, Xu W, Yi X, et al. A novel engineered IL-21 receptor arms T-cell receptor-engineered T cells (TCR-T cells) against hepatocellular carcinoma. Signal Transduct Target Ther. 2024;9(1):101.","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"6475_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.108597","volume":"27","author":"Y Liu","year":"2024","unstructured":"Liu Y, Dang Y, Zhang C, Liu L, Cai W, Li L, Fang L, Wang M, Xu S, Wang G, et al. IL-21-armored B7H3 CAR-iNKT cells exert potent antitumor effects. iScience. 2024;27(1): 108597.","journal-title":"iScience"},{"issue":"6","key":"6475_CR43","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ccr.2011.11.005","volume":"20","author":"M Snuderl","year":"2011","unstructured":"Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20(6):810\u20137.","journal-title":"Cancer Cell"},{"issue":"20 Pt 1","key":"6475_CR44","doi-asserted-by":"publisher","first-page":"6144","DOI":"10.1158\/1078-0432.CCR-05-1418","volume":"12","author":"T Martens","year":"2006","unstructured":"Martens T, Schmidt NO, Eckerich C, Fillbrandt R, Merchant M, Schwall R, Westphal M, Lamszus K. A novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res. 2006;12(20 Pt 1):6144\u201352.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"6475_CR45","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1111\/imr.12773","volume":"290","author":"D Akhavan","year":"2019","unstructured":"Akhavan D, Alizadeh D, Wang D, Weist MR, Shepphird JK, Brown CE. CAR T cells for brain tumors: lessons learned and road ahead. Immunol Rev. 2019;290(1):60\u201384.","journal-title":"Immunol Rev"},{"key":"6475_CR46","doi-asserted-by":"publisher","first-page":"205031212110690","DOI":"10.1177\/20503121211069012","volume":"10","author":"B Mirlekar","year":"2022","unstructured":"Mirlekar B. Tumor promoting roles of IL-10, TGF-beta, IL-4, and IL-35: Its implications in cancer immunotherapy. SAGE Open Med. 2022;10:20503121211069012.","journal-title":"SAGE Open Med"},{"issue":"1","key":"6475_CR47","doi-asserted-by":"publisher","first-page":"7921","DOI":"10.1038\/s41467-024-51978-3","volume":"15","author":"CM Stewart","year":"2024","unstructured":"Stewart CM, Siegler EL, Sakemura RL, Cox MJ, Huynh T, Kimball B, Mai L, Can I, Manriquez Roman C, Yun K, et al. IL-4 drives exhaustion of CD8(+) CART cells. Nat Commun. 2024;15(1):7921.","journal-title":"Nat Commun"},{"issue":"8034","key":"6475_CR48","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1038\/s41586-024-07962-4","volume":"634","author":"B Feng","year":"2024","unstructured":"Feng B, Bai Z, Zhou X, Zhao Y, Xie YQ, Huang X, Liu Y, Enbar T, Li R, Wang Y, et al. The type 2 cytokine Fc-IL-4 revitalizes exhausted CD8(+) T cells against cancer. Nature. 2024;634(8034):712\u201320.","journal-title":"Nature"},{"issue":"1","key":"6475_CR49","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1038\/s41467-022-28523-1","volume":"13","author":"VM Ravi","year":"2022","unstructured":"Ravi VM, Neidert N, Will P, Joseph K, Maier JP, Kuckelhaus J, Vollmer L, Goeldner JM, Behringer SP, Scherer F, et al. T-cell dysfunction in the glioblastoma microenvironment is mediated by myeloid cells releasing interleukin-10. Nat Commun. 2022;13(1):925.","journal-title":"Nat Commun"},{"issue":"11","key":"6475_CR50","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/s41587-023-02060-8","volume":"42","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, Chen J, Andreatta M, Feng B, Xie YQ, Wenes M, Wang Y, Gao M, Hu X, Romero P, et al. IL-10-expressing CAR T cells resist dysfunction and mediate durable clearance of solid tumors and metastases. Nat Biotechnol. 2024;42(11):1693\u2013704.","journal-title":"Nat Biotechnol"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06475-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06475-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T12:02:39Z","timestamp":1745236959000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06475-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,21]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6475"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06475-6","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,21]]},"assertion":[{"value":"20 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study used human whole blood from de-identified healthy donors purchased from a commercial vendor and therefore is not a human subject research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors give their consent to publish this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"This manuscript is associated with a patent (US Patent No. 11,866,493).","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"460"}}